Hypoglycaemia (in violation of the dosing and inadequate diet): headache, severe hunger, nausea, vomiting, fatigue, sleep disturbance, irritability, agitation, decreased concentration, slowed reactions, depression, confusion, impaired vision and speech, aphasia , tremor, paresis, impaired perception, dizziness, weakness, convulsions, bradycardia, delirium, impaired breathing, drowsiness, loss of consciousness with the possible development of coma, or death.
Also can be marked andrenergic reactions: sweating, "sticky" skin, anxiety, tachycardia, hypertension, palpitations, arrhythmia, and angina pectoris.
From the gastrointestinal tract: nausea, vomiting, diarrhea, abdominal pain, constipation (the severity of these symptoms decreases with admission during meals).
From the skin and subcutaneous tissue: rash, itching, urticaria, erythema, maculopapulletic rash, bullous rash.
From the blood and lymphatic system: anemia, thrombocytopenia, leukopenia, granulocytopenia. As a rule, these phenomena are reversible in the event of discontinuation of therapy.
From the liver and bile ducts: increased activity of "hepatic" enzymes (aspartate aminotransferase (ACT), alanine aminotransferase (ALT), alkaline phosphatase), hepatitis (isolated cases). When cholestatic jaundice occurs, therapy should be discontinued.
From the side of the organ of vision: there may be transient visual impairment caused by changes in blood glucose concentration, especially at the beginning of therapy.
Common side effects of sulfonylureas: erythropenia, agranulocytosis, hemolytic anemia, pancytopenia, allergic vasculitis, hyponatremia. Also, against the background of taking other sulfonylurea derivatives, there was an increase in activity "hepatic" enzymes, a violation of liver function (for example, with the development of cholestasis and jaundice) and hepatitis. These manifestations decreased with time after the withdrawal of sulfonylureas, but in some cases led to life-threatening liver failure.